Answers are grounded in this paper and cite their sources.
Eptinezumab is a calcitonin gene-related peptide monoclonal antibody (CGRP mAb) for migraine prevention, offering rapid onset and quarterly intravenous administration. However, evidence regarding patient and healthcare professional (HCP) experiences and its implementation in routine practice remains limited. This study has explored the opportunities and challenges of eptinezumab treatment. This convergent mixed-methods study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. A total of 20 patients with migraine who received eptinezumab and 10 HCPs participated. Monthly headache days (MHDs) and Migraine Disability Assessment (MIDAS) scores were evaluated over 6 months for patients. Semi-structured in-depth interviews explored experiences with eptinezumab treatment for both participant groups, with transcripts analyzed using thematic analysis. Median MHDs decreased from 18.5 (IQR 8.5–28.0) at baseline to 5.0 (2.0–8.0) at Month 3 and 2.5 (1.0–5.0) at Month 6. Median MIDAS scores decreased from 63.5 (30.0–77.5) to 15.0 (1.0–33.0) and 5.0 (0.5–19.5), respectively. Qualitative findings identified three opportunities: improved migraine symptoms and quality of life, favorable treatment experience and acceptability, and addressing unmet needs in patients with migraine who had experienced multiple preventive treatment failures. Patients and HCPs described improved migraine control, restored daily functioning, and favorable tolerability. Three major challenges emerged: financial and access barriers, health-system and service delivery challenges, and treatment-related concerns. High costs and limited reimbursement were the predominant barriers identified by both participant groups. Patients and HCPs perceived eptinezumab as an effective and well-accepted preventive treatment. Although quarterly intravenous administration was viewed favorably, financial barriers and healthcare system constraints remain major obstacles to broader implementation. These findings offer practical insights into integrating CGRP-targeting therapies into routine care. NCT07035197 (ClinicalTrials.gov).
No takes yet. Share an insight, caveat, or question.
Anukoolwittaya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: